scholarly journals The angiotensin type 1 receptor antagonist valsartan attenuates pathological ventricular hypertrophy induced by hyperhomocysteinemia in rats

2006 ◽  
Vol 7 (4) ◽  
pp. 206-211 ◽  
Author(s):  
Salah Kassab ◽  
Taysir Garadah ◽  
Marwan Abu-Hijleh ◽  
Jamal Golbahar ◽  
Solomon Senok ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Ventricular Hypertrophy ◽  
Angiotensin Type

Protective effects of the angiotensin type 1 receptor antagonist losartan in infection-induced and arthritis-associated alveolar bone loss

2015 ◽  
Vol 50 (6) ◽  
pp. 814-823 ◽  
Author(s):  
C. M. Queiroz-Junior ◽  
K. D. Silveira ◽  
C. R. de Oliveira ◽  
A. P. Moura ◽  
M. F. M. Madeira ◽  
...  
Keyword(s):  
Bone Loss ◽  
Receptor Antagonist ◽  
Alveolar Bone ◽  
Alveolar Bone Loss ◽  
Protective Effects ◽  
Angiotensin Type

scholarly journals Angiotensin Type 1 Receptor Blockers in Heart Failure

2020 ◽  
Vol 21 (2) ◽  
pp. 125-131 ◽  
Author(s):  
Khuraijam Dhanachandra Singh ◽  
Sadashiva S. Karnik
Keyword(s):  
Heart Failure ◽  
Ventricular Hypertrophy ◽  
Enzyme Inhibitors ◽  
Angiotensin Receptor Blockers ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Left Ventricular ◽  
Converting Enzyme Inhibitors ◽  
Receptor Blockers ◽  
Angiotensin Type

Homeostasis in the cardiovascular system is maintained by physiological functions of the Renin Angiotensin Aldosterone System (RAAS). In pathophysiological conditions, over activation of RAAS leads to an increase in the concentration of Angiotensin II (AngII) and over activation of Angiotensin Type 1 Receptor (AT1R), resulting in vasoconstriction, sodium retention and change in myocyte growth. It causes cardiac remodeling in the heart which results in left ventricular hypertrophy, dilation and dysfunction, eventually leading to Heart Failure (HF). Inhibition of RAAS using angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) has shown to significantly reduce morbidity and mortality due to HF. ACEi have been shown to have higher drug withdrawal rates due to discomfort when compared to ARBs; therefore, ARBs are the preferred choice of physicians for the treatment of HF in combination with other anti-hypertensive agents. Currently, eight ARBs have been approved by FDA and are clinically used. Even though they bind to the same site of AT1R displacing AngII binding but clinical outcomes are significantly different. In this review, we described the clinical significance of each ARB in the treatment of HF and their clinical outcome.

scholarly journals The Prevention of Renal Injury Progression by Angiotensin Type 1 Receptor Antagonist

1993 ◽  
Vol 34 (4) ◽  
pp. 500-500
Author(s):  
Katsuhiko Kohara ◽  
Hiroshi Mikami ◽  
Naoki Okuda ◽  
Jitsuo Higaki ◽  
Toshio Ogihara
Keyword(s):  
Receptor Antagonist ◽  
Renal Injury ◽  
Injury Progression ◽  
Angiotensin Type
Sign in / Sign up

Export Citation Format

Share Document